-+ 0.00%
-+ 0.00%
-+ 0.00%
Enorama Pharma restores equity to SEK 24.01 million through loan restructuring
Share
Listen to the news
Enorama Pharma restores equity to SEK 24.01 million through loan restructuring
  • Enorama Pharma's board recommends continued operations rather than liquidation at a shareholder vote on December 4, 2026.
  • A USD 2.5 million loan facility from DS Global and debt restructuring restore equity to SEK 24.01 million, eliminating the capital deficiency.
  • Existing loans, including interest, will convert into shares at SEK 0.4 each at maturity unless repaid early, potentially lifting DS Global above 30%.
  • Liquidation is the fallback if shareholders reject continued operations, with shareholder distributions conservatively estimated at SEK 0 per share.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enorama Pharma AB published the original content used to generate this news brief via Cision (Ref. ID: 20261117:BIT:0142:0) on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending